Literature DB >> 21256185

Impaired dopamine release and uptake in R6/1 Huntington's disease model mice.

Andrea N Ortiz1, Benjamin J Kurth, Gregory L Osterhaus, Michael A Johnson.   

Abstract

Huntington's disease (HD) is a progressive, neurodegenerative movement disorder. Here, we used fast-scan cyclic voltammetry to measure dopamine release and uptake in striatal brain slices from R6/1 HD model mice. Peak dopamine release ([DA](max)) was significantly diminished in R6/1 mice (52% of wild-type at 24 weeks of age). Similarly, dopamine released per locally applied electrical stimulus pulse ([DA](p)), which is [DA](max) corrected for uptake and electrode performance, was also diminished in R6/1 mice (43% of wild-type by 24 weeks of age). Moreover, V(max), the maximum rate of dopamine uptake, obtained by modeling the stimulated release plots, was decreased at 16 and 24 weeks of age in R6/1 mice (51 and 48% of wild-type, respectively). Thus, impairments in both dopamine release and uptake appear to progress in an age-dependent manner in R6/1 mice.
Copyright © 2011. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21256185      PMCID: PMC3677767          DOI: 10.1016/j.neulet.2011.01.036

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice.

Authors:  A Petersén; Z Puschban; J Lotharius; B NicNiocaill; P Wiekop; W T O'Connor; P Brundin
Journal:  Neurobiol Dis       Date:  2002-10       Impact factor: 5.996

2.  Determination of release and uptake parameters from electrically evoked dopamine dynamics measured by real-time voltammetry.

Authors:  Q Wu; M E Reith; R M Wightman; K T Kawagoe; P A Garris
Journal:  J Neurosci Methods       Date:  2001-12-15       Impact factor: 2.390

3.  Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.

Authors:  A Petersén; O Hansson; Z Puschban; E Sapp; N Romero; R F Castilho; D Sulzer; M Rice; M DiFiglia; S Przedborski; P Brundin
Journal:  Eur J Neurosci       Date:  2001-11       Impact factor: 3.386

4.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

5.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

6.  Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.

Authors:  Michael A Johnson; Vignesh Rajan; Charles E Miller; R Mark Wightman
Journal:  J Neurochem       Date:  2006-03-29       Impact factor: 5.372

7.  Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.

Authors:  José R Pineda; Josep M Canals; Miquel Bosch; Albert Adell; Guadalupe Mengod; Francesc Artigas; Patrik Ernfors; Jordi Alberch
Journal:  J Neurochem       Date:  2005-06       Impact factor: 5.372

8.  D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism.

Authors:  Elizabeth A Bolan; Bronwyn Kivell; Vanaja Jaligam; Murat Oz; Lankupalle D Jayanthi; Yang Han; Namita Sen; Eneki Urizar; Ivone Gomes; Lakshmi A Devi; Sammanda Ramamoorthy; Jonathan A Javitch; Agustin Zapata; Toni S Shippenberg
Journal:  Mol Pharmacol       Date:  2007-01-31       Impact factor: 4.436

9.  Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum.

Authors:  Andrea N Ortiz; Benjamin J Kurth; Gregory L Osterhaus; Michael A Johnson
Journal:  J Neurochem       Date:  2009-11-19       Impact factor: 5.372

10.  In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.

Authors:  J C Kraft; G L Osterhaus; A N Ortiz; P A Garris; M A Johnson
Journal:  Neuroscience       Date:  2009-04-09       Impact factor: 3.590

View more
  14 in total

1.  Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease.

Authors:  Glenn M Dallérac; Damian M Cummings; Mark C Hirst; Austen J Milnerwood; Kerry P S J Murphy
Journal:  Neuromolecular Med       Date:  2016-01-18       Impact factor: 3.843

2.  Regional differences in dopamine release in the R6/2 mouse caudate putamen.

Authors:  Sam V Kaplan; Ryan A Limbocker; Beth Levant; Michael A Johnson
Journal:  Electroanalysis       Date:  2018-03-30       Impact factor: 3.223

3.  Measurement of Total Antioxidant Capacity in Sub-μL Blood Samples Using Craft Paper-based Analytical Devices.

Authors:  Meng Sun; Michael A Johnson
Journal:  RSC Adv       Date:  2015-06-18       Impact factor: 3.361

4.  LC-MS/MS quantification of salvinorin A from biological fluids.

Authors:  Michael J Caspers; Todd D Williams; Kimberly M Lovell; Anthony Lozama; Eduardo R Butelman; Mary Jeanne Kreek; Matthew Johnson; Roland Griffiths; Katherine Maclean; Thomas E Prisinzano
Journal:  Anal Methods       Date:  2013-12-21       Impact factor: 2.896

5.  Motor function and dopamine release measurements in transgenic Huntington's disease model rats.

Authors:  Andrea N Ortiz; Gregory L Osterhaus; Kelli Lauderdale; Luke Mahoney; Stephen C Fowler; Stephan von Hörsten; Olaf Riess; Michael A Johnson
Journal:  Brain Res       Date:  2012-02-24       Impact factor: 3.252

6.  Untargeted metabolic profiling identifies interactions between Huntington's disease and neuronal manganese status.

Authors:  Kevin K Kumar; Cody R Goodwin; Michael A Uhouse; Julia Bornhorst; Tanja Schwerdtle; Michael Aschner; John A McLean; Aaron B Bowman
Journal:  Metallomics       Date:  2015-02       Impact factor: 4.526

7.  Dopamine Promotes Ascorbate Release from Retinal Neurons: Role of D1 Receptors and the Exchange Protein Directly Activated by cAMP type 2 (EPAC2).

Authors:  Thaísa Godinho da Encarnação; Camila Cabral Portugal; Caio Eduardo Nogueira; Felipe Nascimento Santiago; Renato Socodato; Roberto Paes-de-Carvalho
Journal:  Mol Neurobiol       Date:  2018-02-23       Impact factor: 5.590

Review 8.  Dopamine release in the basal ganglia.

Authors:  M E Rice; J C Patel; S J Cragg
Journal:  Neuroscience       Date:  2011-09-14       Impact factor: 3.590

9.  In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease.

Authors:  Joshua W Callahan; Elizabeth D Abercrombie
Journal:  Front Syst Neurosci       Date:  2011-07-15

10.  Disease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolism.

Authors:  Jennifer L Madison; Michal Wegrzynowicz; Michael Aschner; Aaron B Bowman
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.